Literature DB >> 1970111

Modes of transformation by the human T-cell leukemia viruses.

M T Yip1, I S Chen.   

Abstract

Two pathogenic human retroviruses have been isolated and shown to cause diseases characterized by malignant proliferation of T-cells. Human T-cell leukemia virus type I (HTLV-I) is the virus etiologic agent of adult T-cell leukemia, and human T-cell leukemia virus type II (HTLV-II) has been rarely associated with some forms of leukemia related to hairy-cell leukemia. Understanding the pathogenesis of these retroviruses requires elucidating the mechanism by which HTLV immortalizes cells. Two hypothetical modes of HTLV-induced transformation are discussed in this review. At the cell surface, HTLV particles via as yet unknown receptors have mitogenic effects on T-cell growth. Once HTLV productively infects the cell, it can initiate molecular changes as well. The HTLV genome encodes a viral regulatory protein, Tax, which not only activates HTLV gene expression, but may also induce inappropriate expression of cellular genes involved in cell proliferation. Models are proposed for how these events mediated by HTLV may contribute to T-cell transformation and ultimately, leukemia.

Entities:  

Mesh:

Year:  1990        PMID: 1970111

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  12 in total

1.  CD154 costimulated ovine primary B cells, a cell culture system that supports productive infection by bovine leukemia virus.

Authors:  A Van den Broeke; Y Cleuter; T Beskorwayne; P Kerkhofs; M Szynal; C Bagnis; A Burny; P Griebel
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Human T-lymphotropic virus types I and II.

Authors:  J D Rosenblatt
Journal:  West J Med       Date:  1993-04

3.  Stimulation of virus production and induction of self-syncytium formation in human T-cell leukemia virus type I- and type II-infected T cells by 12-O-tetradecanoylphorbol-13-acetate.

Authors:  M Wolfson; M Lev; I Avinoah; Z Malik; M Löchelt; R M Flügel; A Dombrovski; M Aboud
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

4.  In vivo rescue of a silent tax-deficient bovine leukemia virus from a tumor-derived ovine B-cell line by recombination with a retrovirally transduced wild-type tax gene.

Authors:  A Van Den Broeke; C Bagnis; M Ciesiolka; Y Cleuter; H Gelderblom; P Kerkhofs; P Griebel; P Mannoni; A Burny
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

5.  Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation.

Authors:  C Pique; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

6.  The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency.

Authors:  M Prochazka; H R Gaskins; L D Shultz; E H Leiter
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

7.  Identification of alternatively spliced mRNAs encoding potential new regulatory proteins in cattle infected with bovine leukemia virus.

Authors:  S Alexandersen; S Carpenter; J Christensen; T Storgaard; B Viuff; Y Wannemuehler; J Belousov; J A Roth
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Human T-cell leukemia virus type I infection of monocytes and microglial cells in primary human cultures.

Authors:  P M Hoffman; S Dhib-Jalbut; J A Mikovits; D S Robbins; A L Wolf; G K Bergey; N C Lohrey; O S Weislow; F W Ruscetti
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  Extracellular Tax1 protein stimulates tumor necrosis factor-beta and immunoglobulin kappa light chain expression in lymphoid cells.

Authors:  P F Lindholm; R L Reid; J N Brady
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  A cis element required for induction of the interleukin 2 enhancer by human T-cell leukemia virus type I binds a novel Tax-inducible nuclear protein.

Authors:  M Li; M Siekevitz
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.